Q-omics provides the consensus-scored TOP3BP1 profile across patient tissues and cancer cell-line models. TOP3BP1 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, TOP3BP1 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, TOP3BP1 RNA expression shows 6,286 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LIHC, COAD, and STAD as cancer lineages where TOP3BP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TOP3BP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TOP3BP1 survival associations across molecular data types. TOP3BP1 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TOP3BP1 RNA expression–survival associations across cancer types. High TOP3BP1 expression shows unfavorable associations in LIHC, CHOL and PCPG, but favorable associations in GBM, ESCA and READ. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify LIHC as the clearest survival context for TOP3BP1 RNA expression.
This table summarizes TOP3BP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for TOP3BP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TOP3BP1 shows higher tumor expression in COAD, KIRP, UCEC, BLCA, HNSC and KICH. The COAD box plot shows higher TOP3BP1 RNA expression in tumor versus normal tissue (log2 FC = +0.122, t-test p < 0.001).
This table shows molecular features associated with TOP3BP1 in patient tissues and cancer cell lines. In patient samples, TOP3BP1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
